At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 40 enrolled
Drug / intervention
indacaterol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Randomized, Double-blind, Placebo-controlled, Multicenter, Exploratory, Single-dose Crossover Study With Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
In Brief
A Phase 4 clinical trial evaluating indacaterol and placebo for COPD. Completed, enrolled 40 participants across 6 sites.
Detailed Summary
This is a phase IV study of indacaterol 75 μg single-dose compared to placebo in moderate-severe COPD patients with breathing symptoms to assess time to patient's perception of onset of effect.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
Primary CompletionMar 2012
First PostedMar 2012
TodayJul 2026
First PostedMar 5, 2012
Enrollment StartJan 1, 2012
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.3 years ago
Interventions
indacateroldrug
delivered via single-dose dry-powder inhaler
placebodrug
delivered via single-dose dry-powder inhaler